Novo Nordisk A/S B Shares ADRhedged (NVOH)

Novo Nordisk is a Danish pharmaceutical and biotechnology company best known for its insulins, diabetes treatments, and more recently obesity-related medications that have become blockbusters worldwide. The company is headquartered in Copenhagen and trades primarily on European exchanges. For American investors, the standard way to buy it is through an American Depositary Receipt—a wrapper that lets the share trade on US exchanges, priced in dollars, without the investor holding Danish krone.

The wrapping introduces a problem: currency fluctuation. If Novo Nordisk’s share price in Danish krone goes up 10% and the krone weakens 5% against the dollar, your dollar return is only 4.5%. The krone headwind eats profits. NVOH solves that by hedging the currency daily. It holds the ADRs, but uses swap agreements to neutralize the Danish krone exposure, so the fund tracks the purely stock-price change of Novo Nordisk without currency interference.

The fund and the company

NVOH does not own Novo Nordisk shares directly; it owns American Depositary Receipts, which represent one or more shares of the Danish parent. Each ADR is a standardized contract specifying the conversion ratio. The ADR itself is listed and trades on US stock exchanges, priced in dollars, with US-based custodians holding the underlying Danish shares.

Novo Nordisk is a mid-cap pharmaceutical company by US standards and a major holding in European healthcare indices. It has grown substantially on the back of insulin demand and, more recently, the commercial success of medications for type 2 diabetes and obesity—particularly semaglutide, sold under brand names like Ozempic and Wegovy. The company has legitimate competitive advantages: long-standing relationships with diabetes care networks, manufacturing scale, and a robust pipeline of injectable and oral medications. It also faces the usual pharmaceutical pressures: patent cliffs when blockbusters lose exclusivity, regulatory pricing pressure, and dependence on a narrow set of products.

How the hedging works

The fund uses total return swaps with major banks to lock in the Danish krone exposure. A swap is a contract where the fund agrees to pay the counterparty the krone-denominated return of the ADR position, while the counterparty pays the fund the dollar-denominated equivalent. The math is straightforward: if the ADR price in krone goes up, the fund collects that gain in dollars, and the currency move between krone and dollar is neutralized by the swap structure.

The hedging is reset daily, which means the fund constantly re-establishes the swap ratio based on the previous day’s close. This is important for precision: daily rebalancing ensures that the fund is always tracking the krone-based return, not allowing currency drift to accumulate. It also means the fund incurs small daily costs from roll friction—the bid-ask spreads on renewing the swaps each day. These costs show up in the fund’s tracking error relative to Novo Nordisk’s Danish-traded shares.

Who this fund is for and what it costs

NVOH is designed for US investors who want pure exposure to Novo Nordisk’s healthcare franchise without the complication of currency fluctuation. Someone who believes the company’s pipeline and market position are attractive, but does not have a view on the krone-dollar exchange rate, will find NVOH cleaner than buying the ADR directly.

The costs are: the fund’s expense ratio (higher than a broad US equity ETF, but standard for a single-name hedged fund), the tracking error introduced by daily hedging mechanics and bid-ask friction in the swap market, and the potential for imperfect hedging during extreme market dislocations when counterparties are under stress.

An investor in NVOH is making a bet on Novo Nordisk’s pharmaceutical business—its ability to launch new products, protect franchise margins, navigate drug pricing, and compete in a consolidated industry. The currency hedge removes one variable so the investor can focus on the business itself.

The business risks beneath the fund

Novo Nordisk’s largest exposure is to diabetes and obesity medications. The semaglutide franchise has been transformative, but it is also a concentration risk. If a competitor launches a superior obesity medicine or if reimbursement pressures force prices down, that single franchise drives most of the company’s valuation. The company’s other franchises—hemophilia treatments, growth hormone therapies—are mature and competitive. Patent cliffs are a real risk as blockbuster exclusivities expire.

Novo Nordisk also faces secular pricing pressure in US healthcare and regulatory pressure on obesity drug availability in some countries. The company is majority-owned by a family trust and is registered in Denmark, which can create governance questions for some investors, though the company operates a large manufacturing and research presence in multiple countries.

The currency hedge in NVOH removes krone risk but does not remove these business risks. If Novo Nordisk’s stock underperforms because of pipeline disappointment or pricing pressure, the fund will decline. The hedge is purely a tool to let the investor focus on the pharmaceutical thesis without worrying about the krone-dollar exchange rate.

How to research NVOH

Start with Novo Nordisk’s investor relations materials and annual reports, available in English on the company website, to understand the product portfolio, the sales trajectory of key franchises like semaglutide, patent expiries, and R&D pipeline. The company’s SEC 20-F filing (foreign private issuers file this form instead of a 10-K) provides full financial and risk disclosure.

Examine NVOH’s prospectus for the precise hedging mechanics: which counterparties provide the swaps, what happens if a counterparty defaults, and how accurately the fund has tracked the underlying ADR price. Compare NVOH’s daily returns to the ADR’s daily returns over a trailing period to assess tracking error—a consistent small gap is normal, but larger divergences suggest the hedge is not working as intended.

Track Novo Nordisk’s obesity and diabetes market share, the sales ramp of new products, and any competitive launches that might threaten semaglutide’s pricing or market position. Watch for patent expirations and late-stage pipeline events. And because this is a health-care holding, stay aware of regulatory developments around drug pricing, obesity treatment reimbursement, and GLP-1 access in major markets, which can shift Novo Nordisk’s revenue growth quickly.